Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China

Table 3 Baseline clinical characteristics and procedure characteristics after PSM

Variable	Breast pCR (N=57)	Breast non-pCR (N=327)	p value
Age (years)	47.90 ± 9.43	49.29 ± 10.60
< 50 years	37	30	0.664
≥50 years	24	21
BMI (kg/m²)	23.05 ± 2.98	23.42 ± 2.78
<18.5	3	1	0.180
18.5~24.9	40	33
≥25.0	8	17
Tumor size (cm)	3.56 ± 1.71	3.71 ± 1.86	0.642
Menstrual status
Premenopause	35	35	1.000
Menopause	16	16
cT stage
1	4	5	0.543
2	40	41
3	7	5
cN stage
0	13	15	0.521
1	31	24
2	7	12
Histological type
IDC	48	46	-
ILC	3	4
Others	0	1
ER status
<10%	5	3	0.687
≥10%	46	48
PR status
<20%	28	34	0.327
≥ 20%	23	17
Her2 status (IHC)
−	13	7	0.362
+	21	26
++	17	18
Ki67 status
<15%	6	9	0.549
≥15%	45	42
Surgical type
Mastectomy	47	44	0.508
BCS	4	7
Adjuvant chemotherapy
Yes	15	23	0.169
No	36	28
Adjuvant ET
Yes	50	47	0.250
No	1	4
Adjuvant RT
Yes	34	40	0.307
No	17	11
ypN stage
0	36	9	<0.001
1	10	16
2	4	16
3	1	10
LVI
Yes	3	3	1.000
No	48	48
Recurrence
Yes	4	16	0.002
No	45	33
Death
Yes	4	10	0.146
No	45	39

ISSN: 1477-7819